08 May, 2024

Last Day of Dealings on AIM

London, UK, 8 May 2024 – e-therapeutics plc (AIM: ETX), a company integrating computational power and biological data to discover life-transforming RNAi medicines, provides a further update with regards to the cancellation of admission of the Company’s ordinary shares to trading on AIM (the “Cancellation”), as originally announced on 10 April 2024 and as approved by shareholders at the general meeting held on 29 April 2024.

Shareholders are reminded that the last day of trading in ETX’s ordinary shares on AIM is today, 8 May 2024. Cancellation will become effective at 7:00a.m. on 9 May 2024.

Following Cancellation, shareholders are encouraged to sign up to the Company’s email news alerts via the e-therapeutics website to remain up to date with the Company’s developments as we continue to advance our portfolio and target opportunities as a private company. The Company will maintain its shareholder communications email address – investorrelations@etherapeutics.co.uk - and investors wishing to enter into dialogue with the Company are encouraged to email that address.

Dealing Arrangements

The Company's ordinary shares will be admitted to trading on the JP Jenkins securities matching platform from 9 May 2024. 

JP Jenkins provides a securities matching venue for unlisted or unquoted assets in companies, enabling shareholders and prospective investors to buy and sell shares on a matched bargain basis. JP Jenkins is a trading name of InfinitX Limited and Appointed Representative of Prosper Capital LLP (FRN453007).

Shareholders wishing to trade these securities can do so through their stockbroker. Trades will be conducted at a level that JP Jenkins is able to match a willing seller and a willing buyer. Trades can be conducted, and limits can be accepted, during normal business hours. Shareholders or potential investors can place limits via their existing UK regulated stockbroker.

The indicative pricing for the ordinary Shares (ISIN: GB00B2823H99), as well as the transaction history, will be available on the JP Jenkins website at (https://jpjenkins.com/company/e-therapeutics-plc/).

The provision of the matched bargain facility will be kept under review by the Board and, in determining whether to continue to offer a matched bargain facility, the Company shall consider expected (and communicated) shareholder demand for such a facility as well as the composition of the Company's register of members and the costs to the Company and shareholders.

Following Cancellation, SP Angel Corporate Finance LLP will cease to act as nominated adviser and corporate broker to the Company.